Iterum Therapeutics to Present Data at IDWeek 2022
October 17 2022 - 5:19PM
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a
clinical-stage pharmaceutical company focused on developing next
generation oral and IV antibiotics to treat infections caused by
multi-drug resistant pathogens in both community and hospital
settings, today announced that two posters will be presented at the
Infectious Disease Society of America’s IDWeek 2022.
The hybrid conference will be held from October
19-23 at the Walter E. Washington Convention Center in Washington,
D.C. Posters will be available for registrants on the IDWeek
Interactive Program and the IDWeek Mobile App starting on October
19, 8 a.m. ET. Onsite attendees can view posters from Oct. 20-22
from 8 a.m. to 6 p.m.
Data to be presented at IDWeek 2022 include:
Presentation Title: Impact of
Asymptomatic Bacteriuria on Primary Efficacy Analyses in the
Evaluation of Novel Antimicrobials for the Treatment of Patients
with Urinary Tract InfectionPoster
#: 227Presenter:
Steven AroninTime/Location: Thursday, October
20, 12:15 p.m. - 1:30 p.m. in Hall B+C
Presentation
Title: Murine Efficacy Studies of Sulopenem
Against Bacillus anthracisPoster
#: 1724Presenter: Sailaja
PuttaguntaTime/Location: Saturday, October
22, 12:15 p.m. - 1:30 p.m. in Hall B+C
These Posters will be made available on the
Company’s website on the “Publications: Posters &
Presentations” page under the “Our Science” tab once the conference
ends.
About Iterum Therapeutics
plc
Iterum Therapeutics plc is a clinical-stage
pharmaceutical company dedicated to developing differentiated
anti-infectives aimed at combatting the global crisis of multi-drug
resistant pathogens to significantly improve the lives of people
affected by serious and life-threatening diseases around the world.
Iterum Therapeutics is advancing its first compound, sulopenem, a
novel penem anti-infective compound, in Phase 3 clinical
development with an oral formulation and IV formulation. Sulopenem
has demonstrated potent in vitro activity against a wide variety of
gram-negative, gram-positive and anaerobic bacteria resistant to
other antibiotics. Iterum Therapeutics has received Qualified
Infectious Disease Product (QIDP) and Fast Track designations for
its oral and IV formulations of sulopenem in seven indications.
Investor Contact:Judy
MatthewsChief Financial Officer 312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Apr 2023 to Apr 2024